Infection of CNS by HIV can lead to encephalitis that presents clinically as HIV- associated dementia and HIV-associated neurocognitive disorders ("neuro-AIDS"). Despite the advent of HAART, at the late stage of the disease more than 11% of HIV patients suffer from HIV-associated dementia. Current antiretroviral drugs are ineffective at treating viral infection in the brain, because they cannot freely diffuse across the blood-brain barrier (BBB). Therefore, HIV viral replication persists in the CNS and continues to augment the neuropathogenesis process. The development of antivirals which can cross the BBB is therefore a critical unmet medical need. We propose a new strategy to prevent and treat HIV CNS infection, through application of the results of our recent discoveries. We found that attachment of a cholesterol group ("cholesterol tagging") to a peptide fusion inhibitor (FI) endows it with the ability to penetrate the brain. Use of peptide FI as HIV antivirals is a clinically validated strategy. However, the only FI in clinical use, (enfuvirtide, Fuzeon(R)), cannot penetrate the CNS. The use of cholesterol tagging for BBB penetration would be compounded by two additional advantages: (i) localization of the peptide in the lipid rafts where fusion activation occurs, resulting in dramatically increased antiviral potency, and (ii) binding to plasma lipoproteins, resulting in increased half-life in vivo. Accordingly, we recently described a cholesterol-tagged HIV peptide, which is the most potent FI reported to date, H100-fold more potent than enfuvirtide. We propose here to assess the potential of cholesterol-tagged FI to treat retroviral infection of the CNS, using feline Immunodeficiency Virus (FIV) as a unique and credible model for neuro-AIDS.

Public Health Relevance

At the late stage of HIV infection, as high as 11% of patients develop HIV-associated dementia and HIV- associated neurocognitive disorders. Current drugs, which are highly effective in reducing viral replication, cannot treat infection in the brain, because they cannot freely diffuse across the blood-brain barrier (BBB). Persistent, low level replication of the virus in central nervous system (CNS) thus continues to feed the neuropathogenesis process. The development of antivirals which can penetrate the BBB is therefore a critical unmet medical need. We propose a strategy to deliver an antiviral drug - similar to one already in clinical use (enfuvirtide, Fuzeon(R)) - across the BBB to block HIV infection in the CNS.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21NS076385-02
Application #
8300066
Study Section
NeuroAIDS and other End-Organ Diseases Study Section (NAED)
Program Officer
Wong, May
Project Start
2011-08-01
Project End
2014-01-01
Budget Start
2012-08-01
Budget End
2014-01-01
Support Year
2
Fiscal Year
2012
Total Cost
$191,724
Indirect Cost
$18,886
Name
Weill Medical College of Cornell University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
060217502
City
New York
State
NY
Country
United States
Zip Code
10065
Augusto, Marcelo T; Hollmann, Axel; Castanho, Miguel A R B et al. (2014) Improvement of HIV fusion inhibitor C34 efficacy by membrane anchoring and enhanced exposure. J Antimicrob Chemother 69:1286-97
Welsch, Jeremy C; Talekar, Aparna; Mathieu, Cyrille et al. (2013) Fatal measles virus infection prevented by brain-penetrant fusion inhibitors. J Virol 87:13785-94